Metronidazol Al

Metronidazole, the active ingredient in Metronidazol Al, is a nitroimidazole presented as an oral tablet for systemic administration. It is used to treat anaerobic bacterial infections and selected protozoal infections in both adult and pediatric patients when prescribed by a healthcare professional. It is indicated for conditions such as bacterial vaginosis, trichomoniasis, amoebic dysentery and Clostridioides difficile infection.

GNH USA supplies Metronidazol Al as a licensed, EU‑origin product that complies with Good Distribution Practice, providing reliable supply to hospitals, pharmacies, specialty and transplant centres worldwide through its international procurement network.

Metronidazole is an antibiotic of the nitroimidazole class that targets anaerobic bacteria and certain protozoa.

- Anaerobic bacterial infections: eradicates susceptible anaerobes and reduces infection‑related symptoms. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving genital discharge and irritation. - Amoebic dysentery: kills Entamoeba histolytica trophozoites, controlling intestinal inflammation. - Clostridioides difficile infection: suppresses toxin‑producing C. difficile strains, aiding recovery.

Metronidazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional dull or throbbing head pain. - Diarrhea: loose stools that resolve after therapy.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Peripheral neuropathy: tingling or numbness in extremities, potentially persistent.

Before prescribing Metronidazol Al, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and adjust if necessary. - Hepatic disease: use with caution in patients with liver dysfunction. - Alcohol consumption: avoid alcohol to prevent a disulfiram‑like reaction. - Pregnancy: risk category unknown; weigh benefits against potential risks. - Warfarin co‑therapy: monitor INR closely due to possible increased anticoagulant effect. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metronidazol Al can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: can potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Lithium: may raise lithium levels, risking toxicity. - Cimetidine: can increase metronidazole plasma concentrations. - Phenobarbital: may reduce metronidazole effectiveness by enhancing metabolism.